Clinical trials: Current Major Depressive Disorder
Major Depressive Disorder
Transcranial Direct Current Stimulation Therapy for Major Depression
Depression is a prevalent and debilitating disorder. The most common treatments are antidepressant medications and talking therapies. However, for many individuals, these are not their treatment of choice.
- Trial name
- NCT03632434
- Testing
- transcranial direct current stimulation
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- University of East London
Depression
Treating Depression With Transcranial Direct Current Stimulation (tDCS)
The purpose of this study is to see if transcranial direct current stimulation may improve the symptoms of depression.
- Trial name
- NCT00481988
- Testing
- transcranial direct current stimulation, iomed phoresor transcranial direct current stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Spinal Cord Stimulation for the Treatment of Major Depressive Disorder
This pilot clinical trial will evaluate the efficacy and safety of transcutaneous direct current stimulation (tsDCS) in major depressive disorder.
- Trial name
- SPIDEP (NCT03433339)
- Testing
- Active transcutaneous spinal direct current stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-1 (NCT05455684)
- Testing
- Aticaprant
- Where
- 120 sites in United States, Argentina and 11 more
- Volunteers
- 513 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, MDD
Mechanism of Action of tACS for the Treatment of MDD
The purpose of this research study is to use a specific type of non-invasive brain stimulation known as transcranial alternating current stimulation (tACS) to determine its effects on brain activity (measured with EEG) and mood…
- Trial name
- GLADIATOR2 (NCT03994081)
- Testing
- tACS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder (MDD)
Genomics Used to Improve DEpression Decisions
Evaluate the impact of GeneSight Psychotropic on response to psychotropic treatment as judged by the mean change in the 17-item Hamilton Depression (HAM-D17) score from baseline to end of Week 8 of the study.
- Trial name
- GUIDED (NCT02109939)
- Testing
- GeneSight Psychotropic
- Where
- 61 sites in United States
- Volunteers
- 1,398 people
- Sponsor
- Assurex Health Inc.
Antenatal Depression, Major Depressive Disorder
Pilot Study of Personalized Aperiodic Transcranial Alternating Current Stimulation in Antenatal Depression (PandA-tACS)
The purpose of this study is to develop the safety, feasibility, and tolerability of a personalized transcranial alternating current stimulation (tACS) approach in antenatal depression.
- Conditions
- Antenatal Depression, Major Depressive Disorder, Major Depressive Disorder in Pregnancy, Healthy Controls
- Trial name
- PandA-tACS (NCT06979154)
- Testing
- tACS (aperiodic)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
Empower: tDCS for Major Depressive Disorder at Home
A two-center trial to investigate whether or not active stimulation with the Flow FL-100 tDCS device is superior to sham stimulation for the treatment of major depressive disorder when used at home.
- Trial name
- NCT05202119
- Testing
- Transcranial direct current stimulation
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 174 people
- Sponsor
- Flow Neuroscience AB
Depressive Disorder, Depression
Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
This is a double-blind, sham controlled, multi-center study to confirm the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) for the treatment of patients currently experiencing an episode of depression…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Depressive Episode
- Trial name
- NCT03288714
- Testing
- Synchronized Transcranial Magnetic Stimulation (sTMS)
- Where
- 14 sites in United States
- Volunteers
- 121 people
- Sponsor
- Wave Neuroscience
Major Depressive Disorder, MDD
Transcranial Alternating Current Stimulation for Major Depressive Disorder
Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on patients with Major Depressive Disorder (MDD).
- Trial name
- MDD (NCT02339285)
- Testing
- tACS (alpha), tACS (gamma)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder
The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment…
- Trial name
- NCT03093025
- Testing
- TS-121 10 mg, TS-121 50 mg
- Where
- 22 sites in United States
- Volunteers
- 51 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Major Depressive Disorder
Open Label Extension for GLYX13-C-202, NCT01684163
Examine the safety of long term repeat exposure to GLYX-13 in subjects who participated in GLYX13-C-202.
- Trial name
- NCT02192099
- Testing
- Rapastinel (225 mg/450 mg IV administration)
- Where
- 10 sites in United States
- Volunteers
- 61 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Home-based tDCS in Major Depressive Disorder
The investigators propose a study of telehealth supervised, caregiver-delivered, home-based transcranial direct current stimulation (tDCS) for antidepressant treatment of patients with an acute depressive episode.
- Trial name
- MoodStim (NCT04799405)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Hebrew SeniorLife
Major Depressive Disorder
Augmenting Single-session Behavioral Activation (BA) With Delta-beta Transcranial Alternating Current Stimulation (tACS) for the Treatment of Depression
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can augment the effects of a single session of behavioral activation in participants with major depressive disorder.
- Trial name
- ABBA (NCT05693922)
- Testing
- Delta-beta cross-frequency transcranial alternating current stimulation via the NeuroConn DC-STIMULATOR MC, Single-session behavioral activation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Bipolar Disorder I, Bipolar Disorder II
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of participants with bipolar I/II disorder with a current major depressive episode.
- Conditions
- Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
- Trial name
- NCT03692910
- Testing
- SAGE-217
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biogen
Depression, Major Depressive Disorder
Single Session of tACS in a Depressive Episode
Purpose: Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on healthy participants and participants with mood disorders.
- Conditions
- Depression, Major Depressive Disorder, Premenstrual Dysphoric Disorder, Depressive Episode
- Trial name
- SSDE (NCT03449979)
- Testing
- XCSITE100 Stimulator tACS
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
Intensive tDCS for MDD: Feasibility Study
This will be a prospective, open-label, single-arm study to determine the safety and feasibility of an intensive treatment of transcranial direct current stimulation (tDCS) for major depressive disorder (MDD).
- Trial name
- tDCSintensif (NCT05194267)
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Major Depressive Disorder
Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy
In this Phase 4 trial we will study the safety, tolerability and efficacy of mixed salts amphetamine (MSA), trade name Adderall, augmentation of antidepressant therapy for Major Depressive Disorder (MDD) in depressed outpatient…
- Trial name
- NCT02058693
- Testing
- mixed salts amphetamine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rush University Medical Center
Major Depressive Disorder, Anhedonia
Investigating the Causal Role of Prefrontal Control in Decision-making in Patients With Anhedonia
Investigating whether delta-beta cross-frequency transcranial alternating current stimulation can increase goal-directed behavior in participants with major depressive disorder and elevated symptoms of anhedonia.
- Trial name
- DEBRA (NCT05084924)
- Testing
- Cross-frequency transcranial alternating current stimulation via the NeuroConn Direct Current Stimulator Plus
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of North Carolina, Chapel Hill